Updated Review on Clinically-Relevant Properties of Delafloxacin.
Antibiotics (Basel)
; 12(8)2023 Jul 28.
Article
en En
| MEDLINE
| ID: mdl-37627661
ABSTRACT
The extensive use of fluoroquinolones has been consequently accompanied by the emergence of bacterial resistance, which triggers the necessity to discover new compounds. Delafloxacin is a brand-new anionic non-zwitterionic fluoroquinolone with some structural particularities that give it attractive proprieties high activity under acidic conditions, greater in vitro activity against Gram-positive bacteria-even those showing resistance to currently-used fluoroquinolones-and nearly equivalent affinity for both type-II topoisomerases (i.e., DNA gyrase and topoisomerase IV). During phases II and III clinical trials, delafloxacin showed non-inferiority compared to standard-of-care therapy in the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, which resulted in its approval in 2017 by the Food and Drug Administration for indications. Thanks to its overall good tolerance, its broad-spectrum in vitro activity, and its ease of use, it could represent a promising molecule for the treatment of bacterial infections.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
Antibiotics (Basel)
Año:
2023
Tipo del documento:
Article
País de afiliación:
Francia